IL1B and Mental deterioration: Emerging evidence advocates for precision interventions stratified by inflammatory biomarkers (e.g., CRP > 3 mg/L or IL-6 > 2.5 pg/mL guiding Mediterranean diet prioritization and >11% weight loss targets), behavioral readiness (stage-tailored approaches using the Transtheoretical Model to address diet/exercise adherence separately), and comorbidity profiles (e.g., combining GLP-1 agonists with IL-1β inhibitors in atherosclerotic subgroups or omega-3 neuroprotective regimens for cognitive decline) [51].